SARS-CoV-2 infection protects against rechallenge in rhesus macaques

Chandrashekar, Abishek, Liu, Jinyan, Martinot, Amanda J., McMahan, Katherine, Mercado, Noe B., Peter, Lauren, Tostanoski, Lisa H., Yu, Jingyou +45 more·2020·Science
DOI 10.1126/science.abc4776

Cited by (785)

Items 601–700 of 785

  1. Mice Humanized for MHC and hACE2 with High Permissiveness to SARS-CoV-2 Omicron Replication
    F. le Chevalier, Pierre Authié, Sébastien Chardenoux, M. Bourgine, B. Vesin, Delphine Cussigh, Y. Sassier, I. Fert, Amandine Noirat, K. Nemirov et al. · 2023 · Microbes and infection
  2. Monitoring and immunogenicity of SARS-CoV-2 vaccination of laboratory rhesus monkeys (Macaca mulatta)
    Dan Qi Priscilla Oh, I. Grothe, Herbert Lukaß, A. Kreiter, M. Hoffmann, D. Wegener · 2023 · Scientific Reports
  3. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN
    Jing-You Yu, P. Thomas, K. McMahan, Catherine Jacob-Dolan, Jin-Yan Liu, Xuan He, David L. Hope, E. Martinez, Wei-Hung Chen, Michaela Sciacca et al. · 2022 · Science Advances
  4. Risk and severity of SARS-CoV-2 reinfection among patients with multiple sclerosis vs. the general population: a population-based study
    Mahdi Barzegar, Amirreza Manteghinejad, Sara Bagherieh, Setayesh Sindarreh, O. Mirmosayyeb, Shaghayegh Haghjooy Javanmard, V. Shaygannejad, Maryam Nasirian · 2022 · BMC Neurology
  5. Prospects of animal models and their application in studies on adaptive immunity to SARS-CoV-2
    Xiaohui Wei, Na Rong, Jiangning Liu · 2022 · Frontiers in Immunology
  6. SARS-CoV-2 and Arthropods: A Review
    S. Higgs, Yan-Jang S. Huang, S. Hettenbach, D. Vanlandingham · 2022 · Viruses
  7. COVID-19: A Veterinary and One Health Perspective
    Deepak Kumar, J. Bayry, N. Hegde · 2022 · Journal of the Indian Institute of Science
  8. SARS-CoV-2 testing strategies for outbreak mitigation in vaccinated populations
    Chirag K. Kumar, Ruchita Balasubramanian, S. Ongarello, S. Carmona, R. Laxminarayan · 2022 · medRxiv
  9. An Update on Animal Models for Severe Acute Respiratory Syndrome Coronavirus 2 Infection and Countermeasure Development
    Liang Zhang, Shuai-Yin Chen, Wei-Guo Zhang, Hai-Yan Yang, Yuefei Jin, Guang-Cai Duan · 2021 · Frontiers in Microbiology
  10. Impact of Blinatumomab Treatment on Bone Marrow Function in Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia
    H. Kantarjian, G. Zugmaier, M. Brüggemann, B. Wood, H. Horst, Yi-Fei Zeng, G. Martinelli · 2021 · Cancers
  11. [COVID-19 vaccination: the reality after clinical trials].
    J. Ruiz-Galiana, R. Cantón, P. de Lucas Ramos, Alejandra García-Botella, A. García-Lledó, J. Gómez-Pavón, J. González Del Castillo, T. Hernández-Sampelayo, M. C. Martín-Delgado, F. J. Martín Sánchez et al. · 2021 · Revista Espanola de Quimioterapia
  12. Emerging COVID-19 reinfection four months after primary SARS-CoV-2 infection
    H. Salzer, Matthias J. Neuböck, S. Heldt, I. Haug, C. Paar, B. Lamprecht · 2021 · Wiener Medizinische Wochenschrift
  13. SARS-CoV-2 binding and neutralizing antibody levels after vaccination with Ad26.COV2.S predict durable protection in rhesus macaques
    R. Roozendaal, L. Solforosi, Daniel J. Stieh, J. Serroyen, R. Straetemans, F. Wegmann, S. R. Rosendahl Huber, J. V. D. van der Lubbe, J. Hendriks, M. le Gars et al. · 2021 · bioRxiv
  14. Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study
    M. Provencio, D. Rodríguez-Abreu, A. L. Ortega, G. Serrano, C. Aguado, F. Franco, V. Gutiérrez, Guillermo López Vivanco, M. Guirado, G. Benítez et al. · 2021 · Translational Lung Cancer Research
  15. A longitudinal seroprevalence study in a large cohort of working adults reveals that neutralising SARS-CoV-2 RBD-specific antibodies persist for at least six months independent of the severity of symptoms
    A. Wagner, A. Guzek, J. Ruff, J. Jasińska, Ute Scheikl, Ines Zwazl, Michael Kundi, Hannes Stockinger, Maria R. Farcet, T. Kreil et al. · 2020 · medRxiv
  16. Therapeutic and Vaccine Options for COVID-19: Status after Six Months of the Disease Outbreak
    Dawid Maciorowski, C. Ogaugwu, S. R. Durvasula, R. Durvasula, A. Kunamneni · 2020 · SLAS discovery : advancing life sciences R & D
  17. No current evidence for risk of vaccine-driven virulence evolution in SARS-CoV-2
    Ian F. Miller, C. J. Metcalf · 2020 · medRxiv
  18. SARS-CoV-2 infection induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques
    Sonny R. Elizaldi, Y. S. Lakshmanappa, Jamin W. Roh, B. Schmidt, Timothy D. Carroll, Kourtney D. Weaver, Justin C. Smith, J. Deere, Joseph C. Dutra, M. Stone et al. · 2020 · Research Square
  19. Experimental Models to Investigate Viral and Cellular Dynamics in Respiratory Viral Co-Infections
    Ozge Yazici, C. Vanetti, Mario Clerici, M. Biasin · 2025 · Microorganisms
  20. Intranasal parainfluenza virus-vectored vaccine expressing SARS-CoV-2 spike protein of Delta or Omicron B.1.1.529 induces mucosal and systemic immunity and protects hamsters against homologous and heterologous challenge
    Hong-Su Park, Yumiko Matsuoka, Celia Santos, Cindy Luongo, Xue-Qiao Liu, Li-Juan Yang, Jaclyn A. Kaiser, Eleanor F. Duncan, Reed F. Johnson, I-Ting Teng et al. · 2025 · PLoS Pathogens
  21. NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage
    Hari Balachandran, Kyle W. Kroll, Karen Terry, C. Manickam, Rhianna A. Jones, Griffin Woolley, Tammy Hayes, Amanda J. Martinot, Ankur Sharma, Mark G. Lewis et al. · 2024 · PLoS Pathogens
  22. Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination
    Faustine Montmaneix-Engels, C. Diméglio, Laeticia Staes, I. Da Silva, Marion Porcheron, Isabelle Jougla, Fabrice Hérin, J. Izopet · 2024 · Heliyon
  23. SARS-CoV-2-specific T cell responses wane profoundly in convalescent individuals 10 months after primary infection
    Ziwei Li, Tiandan Xiang, Boyun Liang, Jing Liu, Hui Deng, Xuecheng Yang, Hua Wang, Xuemei Feng, Gennadiy Zelinskyy, Mirko Trilling et al. · 2023 · Virologica Sinica
  24. Longer intervals between SARS‐CoV‐2 infection and mRNA‐1273 doses improve the neutralization of different variants of concern
    J. García-Pérez, M. Bermejo, A. Ramírez-García, H. E. de la Torre-Tarazona, Almudena Cascajero, María Castillo de la Osa, Paloma Jiménez, Marta Aparicio Gómez, Esther Calonge, A. Sancho-López et al. · 2023 · Journal of Medical Virology
  25. Characterization of a Vesicular Stomatitis Virus-Vectored Recombinant Virus Bearing Spike Protein of SARS-CoV-2 Delta Variant
    Wenwen He, Huan Cui, Shen Wang, Bo Liang, Cheng Zhang, Weiqi Wang, Qi Wang, Wu-Jian Li, Yong-Kun Zhao, Tie-Cheng Wang et al. · 2023 · Microorganisms
  26. Differential persistence of neutralizing antibody against SARS-CoV-2 in post immunized Bangladeshi population
    Dipa Roy, Md. Mosfequr Rahman, A. S. Chaity, M. Reza, A. Haque · 2022 · Scientific Reports
  27. SARS-CoV-2-reactive IFN-γ-producing CD4+ and CD8+ T cells in blood do not correlate with clinical severity in unvaccinated critically ill COVID-19 patients
    B. Olea, E. Albert, E. Giménez, I. Torres, P. Amat, M. J. Remigia, J. Alberola, N. Carbonell, J. Ferreres, M. Blasco et al. · 2022 · Scientific Reports
  28. Immunogenicity and protective efficacy of SARS-CoV-2 recombinant S-protein vaccine S-268019-b in cynomolgus monkeys
    Masayuki Hashimoto, N. Nagata, T. Homma, H. Maeda, K. Dohi, N. Seki, Ken Yoshihara, N. Iwata-Yoshikawa, Nozomi Shiwa-Sudo, Yusuke Sakai et al. · 2022 · Vaccine
  29. Intranasal pediatric parainfluenza virus-vectored SARS-CoV-2 vaccine candidate is protective in macaques
    C. Le Nouën, Christine E. Nelson, Xue-Qiao Liu, Hong-Su Park, Y. Matsuoka, Cindy Luongo, Celia Santos, Li-Juan Yang, Richard Herbert, Ashley Castens et al. · 2022 · bioRxiv
  30. Interspecies Comparisons of the Effects of Potential Antiviral 3-Amidinophenylalanine Derivatives on Cytochrome P450 1A2 Isoenzyme
    Zsófia Fedor, Anna Szentkirályi-Tóth, G. Nagy, Zoltán Szimrók, Eszter Varga, Anna Pászti, Z. Pászti, Á. Jerzsele, O. Pilgram, T. Steinmetzer et al. · 2022 · Veterinary Sciences
  31. Development of an In Vivo Probe to Track SARS-CoV-2 Infection in Rhesus Macaques
    Patrick Madden, M. S. Arif, Mark E. Becker, Michael D. McRaven, A. M. Carias, R. Lorenzo-Redondo, Si-Xia Xiao, C. Midkiff, R. Blair, E. L. Potter et al. · 2021 · Frontiers in Immunology
  32. A stark difference in the profiles of defective viral transcripts between SARS-CoV-2 and SARS-CoV
    Dong-Ying Xie, H. Chu, Dong Yang, Qiutao Ding, Gefei Huang, Luo Chen, Zong-Wei Cai, Jian-Dong Huang, Zhong-Ying Zhao · 2021 · Journal of Infection
  33. Heightened COVID-19 Vaccine Response following SARS-CoV-2 Infection
    S. Kelsen, A. Braverman, Puja S. Patel, M. Aksoy, Jacob A. Hayman, C. Rajput, M. Ruggieri, N. Gentile · 2021 · medRxiv
  34. The peripheral T cell population is associated with pneumonia severity in cynomolgus monkeys experimentally infected with severe acute respiratory syndrome coronavirus 2
    N. Nagata, N. Iwata-Yoshikawa, Kaori Sano, A. Ainai, N. Shiwa, Masayuki Shirakura, Noriko Kishida, Tomoko Arita, Yasushi Suzuki, Toshihiko Harada et al. · 2021 · bioRxiv
  35. SARS-CoV-2 Antibody Testing: Important but Imperfect
    J. Stapleton · 2020 · Clinical Infectious Diseases
  36. COVID-19 adaptive humoral immunity models: non-neutralizing versus antibody-disease enhancement scenarios
    Antoine Danchin, O. Pagani-Azizi, G. Turinici, G. Yahiaoui · 2020 · medRxiv
  37. Review of Infective Dose, Routes of Transmission, and Outcome of COVID-19 Caused by the SARS-CoV-2 Virus: Comparison with Other Respiratory Viruses
    S. Karimzadeh, R. Bhopal, Huy Nguyen Tien · 2020 · Preprints.org
  38. Multiplexed proteomics and imaging of resolving and lethal SARS-CoV-2 infection in the lung
    Marian Kalocsay, Z. Maliga, Ajit Johnson Nirmal, Robyn J. Eisert, Gary A. Bradshaw, I. Solomon, Yu-An Chen, R. Pelletier, C. Jacobson, J. Mintseris et al. · 2020 · bioRxiv
  39. COVID-19, Australia: Epidemiology Report 23 (Fortnightly reporting period ending 16 August 2020).
    COVID-19 National Incident Room Surveillance Team · 2020 · Communicable diseases intelligence
  40. Improved COVID-19 Serology Test Performance by Integrating Multiple Lateral Flow Assays using Machine Learning
    Cody T. Mowery, A. Marson, Yun S. Song, Chun Jimmie Ye · 2020 · medRxiv
  41. Modeling the dynamics of COVID19 spread during and after social distancing
    N. Komarova, D. Wodarz · 2020 · medRxiv
  42. Allometric comparison of viral dynamics in the nasal cavity-nasopharyngeal mucus layer of human and rhesus monkey by CFD-HCD approach
    Han-Yu Li, Kazuki Kuga, Kazuhide Ito · 2024 · Comput. Methods Programs Biomed.
  43. Analysis of SARS-CoV-2 Mutations after Nirmatrelvir Treatment in a Lung Cancer Xenograft Mouse Model
    BoKyu Kang, Dongbum Kim, Jinsoo Kim, Kyeongbin Baek, Sangkyu Park, Ha-Eun Shin, Myeong-Heon Lee, Minyoung Kim, Suyeon Kim, Younghee Lee et al. · 2024 · Biomolecules & Therapeutics
  44. Immune response kinetics to SARS-CoV-2 infection and COVID-19 vaccination among nursing home residents—Georgia, October 2020–July 2022
    Z. Chisty, Deana Li, Melia Haile, Hollis Houston, Juliana DaSilva, Rahsaan Overton, A. Schuh, Jenn Haynie, Jacob Clemente, A. Branch et al. · 2024 · PLoS ONE
  45. The panzootic potential of SARS-CoV-2
    Makenzie E. Mabry, Angela Fanelli, C. Mavian, A. Lorusso, Costanza Manes, P. Soltis, Ilaria Capua · 2023 · BioScience
  46. Validation of a SARS-CoV-2 Surrogate Virus Neutralization Test in Recovered and Vaccinated Healthcare Workers
    Lina Mouna, M. Razazian, Sandra Duquesne, A. Roque-Afonso, C. Vauloup-Fellous · 2023 · Viruses
  47. SARS-CoV-2 Kappa Variant Shows Pathogenicity in a Syrian Hamster Model
    P. Yadav, S. Mohandas, A. Shete, Dimpal A. Nyayanit, Nivedita Gupta, D. Patil, G. Sapkal, V. Potdar, M. Kadam, Abhimanyu Kumar et al. · 2022 · Vector Borne and Zoonotic Diseases
  48. Convalescents’ Reports on COVID-19 Experience—A Qualitative Study
    Renata Bogusz, L. Nowakowska, A. Majchrowska, R. Patryn, Jakub Pawlikowski, A. Zagaja, Paweł Kiciński, Magdalena Pacyna, E. Puacz · 2022 · International Journal of Environmental Research and Public Health
  49. Altered Expression of ACE2 and Co-receptors of SARS-CoV-2 in the Gut Mucosa of the SIV Model of HIV/AIDS
    Shuang Hu, E. Buser, J. Arredondo, D. Relyea, Clarissa Santos Rocha, S. Dandekar · 2022 · Frontiers in Microbiology
  50. Multi-Site Proficiency Testing for Validation and Standardization of Assays to Detect Specific Pathogen Free Viruses, Coronaviruses, and Other Agents in Nonhuman Primates
    J. Yee, R. Grant, Andrew J. Haertel, C. Allers, A. Carpenter, K. V. van Rompay, Jeffrey A. Roberts · 2022 · Journal of medical primatology
  51. Prolonged Protective Immunity Induced by Mild SARS-CoV-2 Infection of K18-hACE2 Mice
    L. Bar-On, Moshe Aftalion, Efi Makdasi, David Gur, R. Alcalay, H. Cohen, A. Beth-din, Ronit Rosenfeld, Hagit Achdout, Erez Bar-Haim et al. · 2022 · Vaccines
  52. COVID-19 outbreak among French firefighters, Marseille, France, 2020
    G. Durand, F. de Laval, Albane de Bonet d'Oléon, François Xavier Le Flem, Y. Morin, C. Badaut, G. Grard, C. Brossier, Marion Fossier, A. Dia et al. · 2021 · Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin
  53. A Meta-Analysis of Rhesus Macaques (Macaca mulatta), Cynomolgus Macaques (Macaca fascicularis), African green monkeys (Chlorocebus aethiops), and Ferrets (Mustela putorius furo) as Large Animal Models for COVID-19.
    Alexandra N. Witt, Rachel D Green, A. Winterborn · 2021 · Comparative medicine
  54. Early post-infection treatment of SARS-CoV-2 infected macaques with human convalescent plasma with high neutralizing activity reduces lung inflammation
    K. V. van Rompay, K. Olstad, R. Sammak, Joseph C. Dutra, Jennifer K. Watanabe, J. Usachenko, Ramya Immareddy, Jamin W. Roh, A. Verma, Yashavanth Shaan Lakshmanappa et al. · 2021 · bioRxiv
  55. An Orally Available Cathepsin L Inhibitor Protects Lungs Against SARS-CoV-2-Induced Diffuse Alveolar Damage in African Green Monkeys
    F. Frueh, D. Maneval, R. Bohm, Jason P. Dufour, R. Blair, Kathy Powell, P. Aye, Nadia A. Golden, C. Roy, Skye Spencer et al. · 2021 · bioRxiv
  56. Probable Causes and Risk Factors for Positive SARS-CoV-2 Testing in Recovered Patients: Evidence From Guangzhou, China
    Lei Luo, Dan Liu, Zhou-Bing Zhang, Zhi-Hao Li, C. Xie, Zhenghe Wang, Zong-Qiu Chen, Pei-Dong Zhang, Xi-Ru Zhang, Yu-Jie Zhang et al. · 2021 · Frontiers in Medicine
  57. Primary Immune Response Provides Protective Efficacy against SARS-CoV-2 Reinfection
    Rupendra SHRESTHA, Reena Shrestha, R. Khadka, R. Gyawali · 2021 · JNMA; journal of the Nepal Medical Association
  58. SARS-CoV-2 reinfection
    I. Romera, K. Núñez, M. Calizaya, I. Baeza, R. Molina, J. Morillas · 2021 · Medicina Intensiva
  59. One dose of COVID-19 nanoparticle vaccine REVC-128 provides protection against SARS-CoV-2 challenge at two weeks post immunization
    Maggie Gu, J. Torres, J. Greenhouse, Shannon E. Wallace, Chi-I Chiang, A. Jackson, Maciel Porto, S. Kar, Yu-Xing Li, A. Ward et al. · 2021 · bioRxiv
  60. A new genus of Apsilocephalidae (Diptera) in Mid-Cretaceous Burmese amber
    I. Zulfiqar, A. Wahab, M. U. Saeed, N. Hussain, M. Sabar, M. Bilal, H. Iqbal · 2021 · Biosis:Biological Systems
  61. The Ethics of Deliberate Exposure to SARS‐CoV‐2 to Induce Immunity
    R. Streiffer, David Killoren, R. Chappell · 2021 · Journal of Applied Philosophy
  62. Full Brain and Lung Prophylaxis against SARS-CoV-2 by Intranasal Lentiviral Vaccination in a New hACE2 Transgenic Mouse Model or Golden Hamsters
    Min-Wen Ku, Pierre Authié, M. Bourgine, François Anna, Amandine Noirat, Fanny Moncoq, B. Vesin, Fabien Névo, Jodie Lopez, P. Souque et al. · 2021 · bioRxiv
  63. Laboratory evaluation of SARS-CoV-2 in the COVID-19 pandemic
    B. Parikh, C. Farnsworth · 2021 · Baillière's Best Practice & Research : Clinical Rheumatology
  64. Longevity of seropositivity and neutralizing titers among SARS-CoV-2 infected individuals after 4 months from baseline: a population-based study in the province of Trento
    P. Stefanelli, A. Bella, G. Fedele, S. Fiore, S. Pancheri, E. Benedetti, C. Fabiani, P. Leone, P. Vacca, Ilaria Schiavoni et al. · 2020 · medRxiv
  65. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2): A Perspective Through the Lens of the Veterinary Diagnostic Laboratory
    T. Stokol, D. McAloose, K. Terio, F. Salguero · 2020 · Frontiers in Veterinary Science
  66. COVID-19, Australia: Epidemiology Report 24 (Fortnightly reporting period ending 30 August 2020).
    COVID-19 National Incident Room Surveillance Team · 2020 · Communicable diseases intelligence
  67. Cellular immune response to SARS-CoV-2 infection in humans: a systematic review
    M. Shrotri, M. V. van Schalkwyk, N. Post, Danielle Eddy, C. Huntley, D. Leeman, S. Rigby, S. Williams, W. Bermingham, P. Kellam et al. · 2020 · medRxiv
  68. Некоторые аспекты формирования иммунного ответа у пациентов с COVID-19
    Светлана Бугоркова · 2020
  69. [Pathogenic, clinical and diagnostic characteristics of the SARS-CoV-2 pandemic].
    Bastian Abarca-Rozas, Jocelyn Vargas Urra, J. R. García-Garzón · 2020 · Revista chilena de infectología
  70. In Quest of a COVID-19 Vaccine
    K. Aggarwal, N. Ganguly · 2020
  71. COVID-19 Pandemic and Vaccines
    H. Qaiser, R. Abdullah, T. Iftikhar, Hammad Majeed, I. Imran · 2021 · Alternative Medicine Interventions for COVID-19
  72. Neurological Manifestations of SARS-CoV-2
    Jasmine Miftahof, Blake Bernauer, Chen Sabrina Tan · 2025 · Viruses
  73. BCG immunization mitigates SARS-CoV-2 replication in macaques via monocyte efferocytosis and neutrophil recruitment in lungs
    Mohammad Arif Rahman, K. Goldfarbmuren, Sarkis Sarkis, Massimiliano Bissa, Anna Gutowska, Luca Schifanella, Ramona Moles, M. Doster, H. Andersen, Yogita Jethmalani et al. · 2025 · JCI Insight
  74. Systemic inflammation is associated with worse outcomes from SARS-CoV-2 infection but not neutralizing antibody
    Christopher W. Farnsworth, B. Roemmich, J. Prostko, G. Davis, G. Murtagh, L. Jackson, C. Jacobson, N. Jeanblanc, T. Griffiths, E. Frias et al. · 2025 · Microbiology spectrum
  75. Quantitating SARS-CoV-2 neutralizing antibodies from human dried blood spots
    Katherine Berman, Greta Van Slyke, Hayley Novak, Jean M. Rock, Rachel Bievenue, Amanda K. Damjanovic, Kate L. DeRosa, Gianna Mirabile, K. Phipps, J. Machowski et al. · 2024 · Microbiology spectrum
  76. SARS-CoV-2 antibodies and their neutralizing capacity against live virus in human milk after COVID-19 infection and vaccination: prospective cohort studies.
    Samantha Ismail, Sharon L. Unger, P. Budylowski, S. Poutanen, Yvonne C. W. Yau, Carleigh Jenkins, Shaista Anwer, Natasha Christie-Holmes, Alex Kiss, T. Mazzulli et al. · 2023 · American Journal of Clinical Nutrition
  77. Antibody titers of individuals vaccinated for COVID-19: A systematic review
    Aminoddin M Domado, Homobono Adaza, Andrea P. Beltrán, Leila M Buenviaje, Catherine D Co, Leira R Combalicer, Shiela May A Corona, John Cruz, Maria Adrianne Camille G Dinjotian, Eli Marie S Esperanzate et al. · 2023 · Journal of Biosciences
  78. The Impact of Body Mass Index on the Antibody Titer after Astra Zeneca Vaccination at UTA’45 Vaccine Center
    Stefan Lukas, Diana Laila Ramatillah, Yufri Aldi, Fatma Sri Wahyuni · 2023 · Research Journal of Pharmacy and Technology
  79. The third inactivated vaccine booster dramatically enhanced SARS‐CoV‐2 antibody responses and did not influence the profile of prothrombotic antibody
    Yun-Bao Pan, Shi-Lin Wang, Guo-Hong Liu, Liping Wang, Liu Yang, Xiaojiao Zeng, Chungen Qian, Jun Lin, Zhen-Yu Pan, Yirong Li · 2022 · Journal of Medical Virology
  80. Correlates of protection via modeling
    J. Schiffer · 2022 · Nature Computational Science
  81. SARS-CoV-2 Immunity: Review of Immune Response to Infection and Vaccination
    Rahnuma Ahmad · 2021 · Bangladesh Journal of Medical Science
  82. Longitudinal analysis of severe acute respiratory syndrome coronavirus 2 seroprevalence using multiple serology platforms
    Juan Manuel Carreño, Damodara Rao Mendu, Viviana R. Simon, Masood A Shariff, Gagandeep Singh, Vidya P. Menon, Florian Krammer · 2021 · iScience
  83. Case Report: Reinfection of COVID-19, with second infection less severe
    N. Alsalih, Z. Saeed, H. Thwiny, A. Al-Yasari, A. Alnassar, J. Hobkirk, M. Alsaadawi · 2021 · F1000Research
  84. SARS-CoV-2 transmission from the healthcare setting into the home: a prospective longitudinal cohort study
    S. Craxford, Jessica Nightingale, A. Ikram, B. Marson, Anthony Kelly, Alan Norrish, Amrita Vijay, S. Astbury, Lola Cusin, Waheed Ashraf et al. · 2021 · medRxiv
  85. A Label-Free SARS-CoV-2 Surrogate Virus Neutralization Test and a Longitudinal Study of Antibody Characteristics in COVID-19 Patients
    Yi-Qi R. Luo, C. Yun, I. Chakraborty, Alan H. B. Wu, K. Lynch · 2021 · medRxiv
  86. Update on treatment and preventive interventions against COVID-19: an overview of potential pharmacological agents and vaccines
    Yinan Xiao, Hanyue Xu, Wen Qiang Guo, Yunuo Zhao, Yuling Luo, Ming Wang, Zhiyao He, Zhenyu Ding, Jiyan Liu, Lei Deng et al. · 2020 · Molecular Biomedicine
  87. Narrative review of the novel coronavirus SARS-CoV-2: update on genomic characteristics, transmissions and animal model
    Zhao-Yong Zhang, Lu Zhang, Ai-Ru Zhu, Yan-Qun Wang, Wen-Da Guan, Zhi-Qi Zeng, Jing Sun, Fang Li, Jing-Xian Zhao, Zi-Feng Yang et al. · 2020 · Journal of Thoracic Disease
  88. Transmission and protection against re-infection in the ferret model with the SARS-CoV-2 USA-WA1/2020 reference isolate
    D. Patel, C. Field, K. M. Septer, D. Sim, Matthew J. Jones, T. Heinly, E. McGraw, T. Sutton · 2020 · bioRxiv
  89. Correlation of Body Mass Index (BMI), initial neutralizing antibodies (nAb), ABO group and kinetics of nAb and anti-nucleocapsid (NP) SARS-CoV-2 antibodies in convalescent plasma (CCP) donors: A longitudinal study with proposals for better quality of CCP collections.
    Silvano Wendel, R. Fontão-Wendel, R. Fachini, G. Candelaria, P. Scuracchio, Ruth Achkar, M. Brito, L. F. Reis, A. Camargo, M. Amano et al. · 2020 · medRxiv
  90. Analytical and clinical evaluation of four anti-SARS-CoV-2 serologic (IgM, IgG, and total) immunoassays
    V. Higgins, Anselmo Fabros, Xiao-Yan Wang, M. Bhandari, D. Daghfal, V. Kulasingam · 2020
  91. Molecular Architecture of Early Dissemination and Massive Second Wave of the SARS-CoV-2 Virus in a Major Metropolitan Area
    S. Long, R. Olsen, Paul A. Christensen, David W. Bernard, James J. Davis, M. Shukla, M. Nguyen, M. Saavedra, Prasanti Yerramilli, Layne Pruitt et al. · 2020 · medRxiv
  92. Challenges in the Development of a Vaccine Against COVID-19
    Wei Chen, F. Zhu · 2020 · Engineering
  93. COVID-19 VE HAYVANLAR
    Ahmet Kursat Azkur · 2020 · Veteriner Farmakoloji ve Toksikoloji Derneği Bülteni
  94. COVID-19, Australia: Epidemiology Report 22 (Fortnightly reporting period ending 2 August 2020).
    COVID-19 National Incident Room Surveillance Team · 2020 · Communicable diseases intelligence
  95. A systematic review uncovers a wide-gap between COVID-19 in humans and animal models
    Salleh N. Ehaideb, Mashan L. Abdullah, B. Abuyassin, A. Bouchama · 2020 · medRxiv
  96. The Uncertainties Underlying Herd Immunity against COVID-19
    F. Rahimi, A. Talebi Bezmin Abadi · 2020
  97. SARS-CoV-2 and mosquitoes: an extreme challenge
    Yan-Jang S. Huang, D. Vanlandingham, Ashley N. Bilyeu, Haelea M. Sharp, S. Hettenbach, S. Higgs · 2020
  98. SARS-CoV-2 infection: diagnostic testing results occasionally require special attention
    E. Riva, P. P. Sainaghi, O. Turriziani, G. Antonelli, G. Patti · 2020 · Emerging Microbes and Infections
  99. Pandemic Viruses at Hajj: Influenza and COVID-19
    Mohammad Alfelali, P. Koul, H. Rashid · 2021 · Handbook of Healthcare in the Arab World
  100. Exposure route drives SARS-CoV-2 infection patterns in non-human primates
    Celine E. Snedden, Dylan H. Morris, T. C. Friedrich, J. O. Lloyd-Smith · 2026 · bioRxiv